Recent epidemiological developments demonstrated that
Introduction
Vaccines and antiviral drugs are essential means for control of influenza [1] . The fast spread and frequent mutation rate of influenza viruses contribute to high incidence and variability of these viruses in seasonal, epidemic, and pandemic influenza [2, 3] . The area-wide and permanent circulation of swine influenza A viruses together with the possibility of interspecies transmission and replication of avian and human influenza A viruses enables reassortment of new viruses in pigs [4] [5] [6] [7] [8] [9] . As shown by the emergence of pandemic influenza A H1N1(2009) virus (pH1N1/ 2009) such reassorted viruses can represent a worldwide threat [10] [11] [12] . The antigenic properties as well as drug susceptibility of pH1N1/2009 are determined by gene segments of swine influenza A viruses. In particular, pH1N1/2009 became resistant to M2 channel inhibitors [13, 14] by accepting the matrix protein-coding gene of European swine influenza A viruses which confers the drug resistance [15, 16] . Since H3N2 viruses circulating in humans are also resistant to this drug class [17, 18] a situation of nearly 100% prevalence of ion channel inhibitor resistance was caused worldwide and neuraminidase inhibitors (NAI) like TamifluH and RelenzaH are the only drugs considered for additional prophylactic use at the moment.
The current knowledge about the efficacy of existing NAI against Eurasian swine influenza A viruses is based only on in vitro data [19, 20] . To extend this knowledge, in the present study the efficacy of vaccination as well as the application of TamifluH against two Eurasian swine influenza A viruses was compared under experimental conditions in their natural host. The protective effect of vaccination was comparatively studied in a vaccine-heterologous as well a vaccine-homologous challenge.
Results

Comparison of efficacy of vaccination and TamifluH treatment against H1N1/1981 (vaccine-heterologous challenge)
H1N1/1981 had been isolated within the first period after introduction of avian-like viruses into the European pig population [21, 22] . Because the vaccine strain H1N1/2003 was isolated after 22 years of evolution of these viruses in pigs and vaccinated pigs do not cross-react in HI with H1N1/1981, challenge with H1N1/ 1981 allows studying the efficacy of vaccination against heterologous challenge with a not cross-reactive strain of the same influenza A virus subtype in comparison to the prophylactic effect of TamifluH.
Just 24 hours after infection with H1N1/1981 unvaccinated untreated pigs developed influenza with dyspnoea diagnosed until day 3 p.i. (Fig. 1A) . Coughing was observed rarely in individual animals only (data not shown). Furthermore, a significant rise in body temperature was observed on day 1 p.i. (Fig. 1B) . Vaccination and TamifluH treatment significantly reduced clinical signs ( Fig. 1A and 1B) . Reduction of body weight was not observed (data not shown).
Up to 6 days p.i. infected, untreated as well as TamifluH-treated pigs shed virus (Fig. 1C) . Thereafter, virus titres decreased markedly coinciding with the appearance of first antibodies against the challenge strain (Fig. 2) . All (12/12 pigs until day 2 p.i., 7/7 pigs from day 3 to 5 p.i.) untreated and unvaccinated pigs had virus titres in their nasal swabs ranging from 1.3 to 3.7 log 10 EID 50 /ml. On day 6 p.i. 4 of 7 pigs of this group shed virus (0.9-1.3 log 10 EID 50 /ml). On day 7 p.i. virus shedding ceased. TamifluH-treated pigs showed following shedding data: day 1 p.i. 9/10 pigs 1.3-2.7 log 10 EID 50 /ml, day 2 p.i. 9/10 pigs 0.7-1.7 log 10 EID 50 /ml, day 3 p.i. 4/5 pigs 1.3-2.7 log 10 EID 50 /ml, day 4 p.i. 5/5 pigs 0.9-2.5 log 10 EID 50 /ml, day 5 p.i 4/5 pigs 1.3-3.3 log 10 EID 50 /ml, day 6 p.i. 4/5 pigs 0.7-1.7 log 10 EID 50 /ml, day 7 p.i. 0/5 pigs. Vaccinated pigs had following shedding profile: day 1 p.i. 5/10 pigs 1.3-2.5 log 10 EID 50 /ml, day 2 p.i. 2/10 pigs 0.7-3.3 log 10 EID 50 /ml, day 3 p.i. 5/5 pigs 0.7-3.3 log 10 EID 50 /ml, day 4 p.i. 3/5 pigs 1.3-2.9 log 10 EID 50 /ml, day 5 2/5 pigs 0.7-0.9 log 10 EID 50 /ml, day 6 p.i. 0/5 pigs, day 7 p.i. 0/5 pigs. At some time points the mean virus titre in nasal swabs of the vaccinated and the TamifluH-treated group was significantly lower than in the control group (Fig. 1C) . However, one day after TamifluH treatment had been stopped, virus titres in nasal swabs increased. comparison to RESPIPORCH FLU3-vaccinated (n = 10) and untreated animals (n = 12). Dyspnoea (A), rectal temperatures (B), virus titres in nasal swabs, n = 10 animals/group/day until day 2 p.i. and n = 5 from day 3 p.i. on, exception: n = 12 untreated animals at day 0 to 2 p.i. and n = 7 untreated animals/day at 3 to 7 p.i. (C), and mean of histopathological scores with standard deviations and representative photographs of formalin fixed, HE stained lungs (D) are shown (am morning; pm afternoon; p statistical probability: *p,0.05, **p,0.01, ***p,0.001, a vaccinated group versus control group, b TamifluH-treated group versus control group, c vaccinated group versus TamifluH-treated group, Mann-Whitney-U-test). The detection limit of virus titre determination is shown as dotted line (C). doi:10.1371/journal.pone.0061597.g001 , and untreated pigs (C). Geometric mean and standard deviation of antibody titres determined in serum samples of 10 vaccinated and TamifluH-treated or 12 control animals/ /day are shown until day 2 p.i. and 5 or 7 from day 3-10 p.i., respectively. Mann-Whitney-U-test was used to calculate p statistical probability: *p,0.05, **p,0.01, ***p,0.001. Only significant differences are shown. The detection limit of HI antibody titre determination is shown as dotted line. doi:10.1371/journal.pone.0061597.g002
On day 2 p.i, very similar, high virus load was determined in lungs of untreated, vaccinated and TamifluH-treated H1N1/1981-challenged pigs (Table 1) . On day 10 p.i., there was no infectious virus (data not shown).
Macroscopic lung lesions of control pigs mainly affected the margins of the cardiac lobes, followed by lesions on the margins of the apical lobes. The diaphragmatic lobe was only rarely affected near to the cardiac lobe. In general the extent of lung consolidation did not exceed 5-10% of the lung surface. On day 2 p.i., a protective effect was neither observed in TamifluH-treated nor in FLU3-vaccinated animals. Two vaccinated pigs had larger lung lesions than any other pig. On day 10 p.i., lesions were significantly lower in vaccinated pigs and TamifluH-treated pigs (Table 1) . A histopathological score of about 3 and 2 was detected in untreated, infected as well as TamifluH-treated pigs on day 2 and 10 p.i. (Fig. 1D ). Despite similar virus replication in the lung, a significantly lower histopathological score was observed in vaccinated pigs at both time points (Fig. 1D) .
After first vaccination with FLU3 marginal antibody titres to the vaccine strains H1N1/2003 and H1N2/2000 were detected ( Fig. 2A) . These antibodies had risen to highly significant titres after second vaccine administration and did not differ significantly between H1N1/2003 and H1N2/2000. The challenge induced a strong H1N1/1981-specific antibody response on 6 days p.i. in vaccinated pigs whereas it was observed in pigs of the TamifluHtreated as well as the untreated group two days later ( Fig. 2A, B 
Comparison of efficacy of influenza vaccination and TamifluH treatment against H1N2/2000 (vaccinehomologous challenge)
The FLU3 vaccine contains a high passage of strain H1N2/ 2000. Therefore, challenge with the same H1N2 enables studying the effect of vaccination against homologous virus infection.
Influenza induced by H1N2/2000 in untreated, infected control animals was characterized by two dyspnoea peaks on day 1 and 4 p.i ( Fig. 4A ) and temperature .41uC on day 1 p.i. (Fig. 4B ). All pigs recovered from clinical signs within 5 days. Clinical signs were neither observed in vaccinated nor in TamifluH-treated pigs. None of the H1N2/2000-infected animals lost body weight (results not shown).
Vaccination as well as TamifluH-treatment caused a significant virus titre reduction in nasal swabs (Fig. 4C ). All unvaccinated, untreated pigs shed virus from day 1 to 5 p.i. Virus titres ranged from 1.3 to 2.7 log 10 EID 50 /ml. Mean virus titres of TamifluHtreated pigs were significantly reduced from 1 to 4 days p.i. (day 1 p.i. 6 of 10 pigs -6/10 pigs -shed virus at titres ranging from 0.7-0.9 log 10 EID 50 /ml, day 2 p.i. 5/10 pigs 0.7-1.3 log 10 EID 50 /ml, day 3 p.i. 2/5 pigs 0.7-2.1 log 10 EID 50 /ml, day 4 p.i. 3/5 pigs 0.9-2.3 log 10 EID 50 /ml). After stopping TamifluH-treatment H1N2/ 2000 shedding increased in four of five pigs on day 5 (1.3-2.3 log 10 EID 50 /ml) but vanished already 6 days p.i. due to the appearing antibodies (Fig. 4C , 5B). In contrast, five of 10 pigs of the vaccinated group did not shed the virus at all. Low virus titres of 0.7 log 10 EID 50 /ml were detected in the nasal swabs of three vaccinated pigs 24 h p.i., from a fourth pig from day 2 to 5 p.i. (1.1, 2.3, 1.3, and 1.3 log 10 EID 50 /ml), and in the fifth only on day 5 p.i. (1.1 log 10 EID 50 /ml). While vaccination completely prevented H1N2/2000 replication in lungs of vaccinated pigs, the viral titres between the TamifluH-treated and untreated animals did not differ ( Table 1) .
The mean extent of lung consolidation of control animals challenged with H1N2/2000 ranged from 1.9 to 3.0% (Table 1) . Vaccinated pigs had few or no lesions at all on day 2 and 10 p.i. A significantly reduced lung histopathology was also observed in vaccinated pigs in comparison to untreated, unvaccinated pigs on days 2 and 10 p.i. (Fig. 4D) . A high mean histopathological score of about 3 was characteristic for lung tissue samples of untreated as well as TamifluH-treated pigs on day 2 p.i. (Fig. 4D) . Whereas in control animals lung histology worsened till day 10 p.i., an improvement was observed in TamifluH-treated pigs (3.2 versus 2.3; not significant, Fig. 4D ).
Highly significant levels of H1N1/2003-and H1N2/2000-specific HI antibodies were induced by FLU3 vaccination and not further boosted by challenge with H1N2/2000 (Fig. 5A) . Antibodies to H1N2/2000 appeared in untreated (Fig. 5B) and TamifluH-treated (Fig. 5C ) animals between day 6 and 8 p. 
Discussion
High-dose aerosol infection of pigs with H1N1/1981 and H1N2/2000 caused sudden onset of high fever and dyspnoea like influenza in humans [2, 3] . Compared with pig infection trials reported so far the observed clinical symptoms were stronger [23] [24] [25] [26] [27] [28] . These similarities between influenza in aerosol-infection pig models and influenza in humans and pigs in addition to the similar disease course induced by H1N1/1981 and H1N2/2000 provided a good basis for comparatively evaluating the efficacy of vaccination against heterologous and homologous challenge as well as NAI treatment in the present study. The results reveal different degrees of protection.
Like in humans [29, 30] , (i) vaccination as well as TamifluHtreatment significantly reduced clinical symptoms and virus shedding whereas (ii) vaccination was less effective when the challenge occurred with heterologous H1N1/1981 than with homologous H1N2/2000. The faster and stronger antibody response against the heterologous challenge strain H1N1/1981 may explain the efficacy of vaccination in the absence of virusspecific HI antibodies against the challenge virus. It suggests a certain degree of reactivity between older and more recent H1N1 strains. The latter could also account for detection of crossprotecting HI antibodies against pH1N1/2009 that concurs strongly with recently published studies [31] [32] [33] [34] . Moreover, a higher antibody response against the vaccine strain H1N1/2003 was detected after H1N1/1981 challenge reflecting the ''antigenic sin'' [35, 36] . Additionally, NI can contribute to the protective effect seen after vaccination and heterologous challenge. N1 crossreacting NI antibodies were detected indicating that neuraminidases of H1N1 strains are still antigenetically related to each other. Moreover, major histocompatibility complex restricted epitopes conserved in nucleoprotein and matrix protein could be involved in protection as discussed for human seasonal influenza A viruses and pH1N1/2009 virus [37] . European swine influenza A viruses share similar nucleoprotein, matrix, and polymerase genes.
Marked differences were found comparing the efficacy of the studied preventive measures regarding lung viral load, macroscopic lesions, and inflammation. The lack of virus inhibition in the lung after vaccination and heterologous challenge reflects the pathogenic role of antigenetic drift in European swine Influenza A (H1N1) viruses between 1981 and 2003. It also demonstrates a low efficacy of TamifluH regarding this study parameter. Macroscopic lung lesions were almost absent after vaccination and homologous challenge. They were also reduced by TamifluH treatment as well as in vaccinated, heterologous challenged pigs on day 10 p.i. after primary enhancement on day 2 p.i. Based on similar observations until day 5 p.i., Gauger et al. postulated that vaccination may potentiate influenza following challenge with divergent homosubtypic viruses that do not share cross-reacting hemagglutinin or serum neutralizing antibodies [32] . But, the significant reduced lung consolidation on day 10 p.i. reported here suggests that this effect is transient and reversed by antibodies specific to the challenge virus. With regard to inflammation, a significant score reduction was found after vaccination but not after drug treatment. Taken together, these results suggest that the pathogenetic processes which lead to induction of disease are blocked at different stages by vaccination and TamifluH. The latter prevented disease despite high viral lung load and interstitial lymphoid tissue hyperplasia. Two further aspects should be mentioned concerning TamifluH treatment. First, the increased virus shedding one day after drug cessation suggest a need for prolonged treatment of pigs until the appearance of protective antibodies in serum. Detection of virusspecific protective antibodies in the blood correlating with virus clearance in the nose underlines this conclusion. Secondly, H1N2/ 2000 but not H1N1/1981 is additionally glycosylated at Asn163 in the HA and NAI-resistant in cell culture [19] . Glycosylation in position 163 of HA hampers the HA-NA balance and reduces NAI efficacy in vitro [38] . In contrast to in vitro results however, the prevention of influenza in pigs indicates that HA glycosylation at Asn163 does not necessarily affect the efficacy of TamifluH in the natural host.
In summary, due to the high similarity in the course of influenza A virus infection in pigs and seasonal influenza in humans, the pig infection model described here provides a valuable tool for antiviral investigations. In comparison of the tested preventive measures (vaccination and treatment with TamifluH), all protected against disease. Vaccination provided the most optimal protection at homologous challenge. Here, virus replication and histopathological changes in the lung were prevented. Animals 64 crossbred swine (Piétrain6Large White; 48 males and 16 females; IDT Biologika GmbH, Dessau-Roßlau, Germany) born on the same farrowing occasion were used in the present study. Pigs had been proved to be free of influenza during their life span as well as free of maternally-derived antibodies against pH1N1/ 2009, avian H1N1 and human H1N2 influenza A viruses. They were housed in identical isolation rooms based on their challenge status and were provided with feed and water ad libitum.
Materials and Methods
Ethics Statement
Cells and Viruses
Compounds
Commercially available TamifluH capsules (F. Hoffmann-La Roche AG, Basel, CH, batch B113313, 75 mg oseltamivir per capsule) were used for in vivo antiviral studies according to summary of product characteristics. 
Experimental Design
Group classification and experimental conditions. Two independent trials, one with H1N1/1981 (heterologous challenge with homosubtypic virus not cross-reactive to sera of vaccinated pigs) and another with H1N2/2000 (homologous challenge with the same strain as in the vaccine highly cross-reactive to sera of vaccinated pigs) were performed. The experimental design is summarized in Table 2 . In each trial 32 pigs were allotted randomly into 3 groups. One group of 10 pigs was vaccinated i.m. with 2.0 ml of FLU3 21 and 7 days before challenge. Another group of 10 pigs was treated orally with TamifluH starting with 2 capsules the evening before challenge. Then, 2 TamifluH capsules were administered twice daily for 4 days. The third group included 12 unvaccinated untreated pigs as control.
At an age of 11 weeks, pigs of all 3 groups were simultaneously challenged by one-hour-aerosol exposure. Study Parameters and Sampling. After infection, rectal temperatures and signs of respiratory disease, dyspnoea, and cough were recorded twice daily 1-3 days p.i. and daily from 4-10 days p.i. Dyspnoea was assessed as follows: 1, increased respiratory frequency and moderate flank movement; 2, marked breathing difficulty and severe flank movement; 3, laboured breathing affecting the entire body, pronounced flank movement and substantial movements of the snout, 4, extreme breathing difficulty reflecting substantial lack of oxygen. Body weights were recorded daily. Nasal swab samples were collected daily in 2.0 ml stabilisation medium containing 60 ml Dextran-Sucrose-Glutamate solution (DSG 72: 126 g dextran 40, 1,5 kg sucrose, 3,6 g potassium-L-glutamate-monohydrate, 5 g potassium-dihydrogenphosphate, 12,5 g potassium-monohydrogen-phosphate, made up to 10 l with water ad injectionem, IDT Biologika GmbH, DessauRosslau, Germany, internal use), 0.2 ml gentamycin (Fagron GmbH, Barsbüttel, Germany), 2 ml amphotericin B (SigmaAldrich, Taufkirchen, Germany), made up to 200 ml with cell culture medium (IDT Biologika GmbH, Dessau-Roßlau, Germany, internal use).
In each trial 5 animals of each group were stunned by electrical stunning tongs 2 days p.i. and bled to death. On 10 days p.i. the remaining animals were slaughtered in the same way.
Lung tissue samples were taken from each lobe for virus detection. Samples of the right and left halves of the lungs were pooled, ground with sterile sea sand, and diluted 1:10 in dilution medium (1.0 ml Amphotericin B and 0.1 ml Gentamycin, made up to 100 ml with phosphate buffered saline solution). Additionally, lung tissue was collected and fixed in 10% neutral buffered formalin for histopathological evaluation.
Blood samples for immunological analysis were taken immediately before the first and second vaccinations, 7 days after the second vaccination (before challenge), and 2, 4, 6, 8, and 10 days p.i.
Hemagglutination Inhibition (HI) Assay
Sera were pre-treated with neuraminidase (Sigma, EC3.2.1.18 Type IV from Clostridium perfringens, 14-18 h at 37uC). After adding sodium citrate (1.5%) inactivation was carried out (30 minutes at 56uC), followed by adsorption to chicken erythrocytes (1 h at 4-8uC).
8 hemagglutinating units (HU) of the 3 vaccine strains, H1N1/ 1981, and pH1N1/2009 were used as antigens and incubated with 1:10 prediluted sera in microtitre plates for 30 min at room temperature. Then a 0.5% chicken erythrocyte suspension was added and incubated for 30 min at room temperature.
Determination of 50% Egg Infectious Dose (EID 50 )
Dilution series (log 10 ) from both lung and nasal swab samples were injected into the allantois cavity of 11-day-old chicken embryos (0.1 ml; 5 eggs per dilution). After sealing the perforation point eggs were incubated at 37uC and checked daily for vitality using an egg candler. On day 4 p.i., the allantois fluid was collected and tested in the hemagglutination test. The Spearman and Kaerber method was used to calculate the EID 50 from the hemagglutinating activity [39, 40] . The detection limit was 0.7 log 10 EID 50 /ml.
NA Inhibition (NI)
NI was analyzed using modified protocol of Sandbulte et al. [41] . Briefly, OD was measured at wavelength 550 nm. For data analysis, the absorbance of the fetuin control wells was subtracted from the OD values and the dilution of sera that resulted in a reading equal to 50% of the positive control (virus, no serum) was determined. The inverse of this dilution was the NI titre. Assay validity was supported by positive control samples (virus+fetuin) with mean absorbance of 0.7-1.3, negative control samples (fetuin only) with mean absorbance ,0.08, and control serum which did not significantly inhibit NA activity.
Lung Pathology and Histopathology
The pathology of the lungs was evaluated macroscopically, photographs were taken, and observed lesions were recorded onto a lung diagram. Percentage of affected lung surface area was assessed for each lobe at dorsal and ventral view.
Formalin-fixed lung tissue samples were embedded in paraffin. 5 mm-thick sections were stained with haematoxylin and eosin for light microscopy. Inflammation was scored on a semi quantitative scale from 0-4: 0, no inflammation; 1, discreet interstitial alveolar macrophages; 2, slight interstitial bronchial associated lymphoid tissue hyperplasia; 3, distinct interstitial alveolar macrophages; 4, distinct interstitial and massive broncholuminal alveolar macrophages.
Statistical Analysis
Mann-Whitney-U-test was performed to evaluate statistical significances. 
